|
|
|
|
|
À¯·áȸ¿ø °áÀç½Ã¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸¸¦
ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
À¯·áÁ¤º¸¸ñ·ÏÀº Àü¹®È¸¿øÀ¸·Î
·Î±×ÀÎ ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
|
|
|
 | Çã°¡Á¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå »óÇÑ±Ý¾× |
[A12950761]
[º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸]
\0 ¿ø/1Á¤(2006.03.01)(ÇöÀç¾à°¡)
\481 ¿ø/1Á¤(2001.09.01)(º¯°æÀü¾à°¡)
[»óº´ÄÚµåÁ¶È¸]
[Áúº´ÄÚµåÁ¶È¸]
|
| ºü¸¥Á¶È¸ |
|
| Á¦Ç°¼º»ó |
´ãȲ»ö ¿øÇüÀÇ Á¦ÇÇÁ¤ [Á¦ÇüÁ¤º¸ È®ÀÎ] |
| Æ÷À塤À¯Åë´ÜÀ§ |
60TABS |
| È¿´ÉÈ¿°ú |
[ÀûÀÀÁõ º° °Ë»ö]
·ù¸¶Æ¼¾ç °üÀý¿°(°ú°Å ºñ½ºÅ×·ÎÀ̵强 ¼Ò¿°ÁøÅëÁ¦¿¡ ÀÇÇØ ÃæºÐÇÑ È¿°ú¸¦ ¾òÁö ¸øÇÑ °æ¿ì).
[Drugbank ÀÇ ¼ººÐÁ¤º¸¿¶÷] [Auranofin]
|
| ¿ë¹ý¿ë·® |
* Àý´ë ÀÓÀǺ¹¿ëÇÏÁö ¸¶½Ã°í ¹Ýµå½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇϽñ⠹ٶø´Ï´Ù.
[󹿾à¾î]
[ÁÖ¼ººÐÄÚµå:112101ATB ¿¡ µû¸¥ ½É»çÁöħ¿¶÷] ¼ºÀÎÀº ¿À¶ó³ëÇÉÀ¸·Î¼ 1ȸ 3mg, 1ÀÏ 2ȸ °æ±¸Åõ¿©Çϰųª 1ȸ 6mg, 1ÀÏ 1ȸ Åõ¿©ÇÑ´Ù. ¿¬·É, Áõ»ó¿¡ µû¶ó ÀûÀýÈ÷ Áõ°¨ÇÑ´Ù.
|
| ±Ý±â |
±Ý ¶Ç´Â Á߱ݼӿ¡ °ú¹ÎÁõ ȯÀÚ, Ç÷¾×Àå¾Ö ¶Ç´Â ±× ±â¿Õ·ÂÀÚ, ½ÅÀå¾Ö ȯÀÚ, °£Àå¾Ö ȯÀÚ, ½ÉÇÑ ¼³»ç, ¼Òȼº ±Ë¾ç ȯÀÚ, Àü½Å¼º È«¹Ý»ó ·çǪ½º(SLE) ȯÀÚ, ±«»ç¼º Àå°áÀå¿° ȯÀÚ, ¾ÆÅäÇǼº ÇǺο° ¹× ¹ÚÅ»¼º ÇǺο°ÀÇ ±â¿Õ·ÂÀÚ, Æó¼¶À¯Áõ ȯÀÚ.
|
| ½ÅÁßÅõ¿© |
º»Á¦¿¡ ÀÇÇÑ ºÎÀÛ¿ëÀÇ ±â¿Õ·ÂÀÚ, ½ÉÇÑ ¼ÒȱâÀå¾Ö¡¤½ÅÀå¾Ö¡¤°£Àå¾ÖÀÇ ±â¿Õ·ÂÀÚ, °ú¹ÎÁõÀÇ ±â¿Õ·ÂÀÚ, µÎµå·¯±â¡¤°Ç¼± µî ¸¸¼º¹ßÁø ȯÀÚ.
|
| ÀÌ»ó¹ÝÀÀ |
- ÇǺÎ:
¹ßÁø, °¡·Á¿òÁõ ¶§¶§·Î ±¸³»¿°, ¼³¿°, Å»¸ð, °á¸·¿°, µÎµå·¯±â, È«¹Ý, ±¤°ú¹ÎÁõ µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
¼Òȱâ: ¼³»ç, ¿¬º¯ ¶§¶§·Î À§Åë, º¹Åë, ¼ÒȺҷ®, ±¸¿ª, ±¸Åä, ½Ä¿åºÎÁø, À§ºÎÆØ¸¸, ÇÏÇ÷, º¯ºñ, ±¸°¥ µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¸ç Àå±âÅõ¿©½Ã À§Àå°ü¿¡ ´ëÇÑ ºÎÀÛ¿ë Æ¯È÷, À§ÀåÃâÇ÷, ¼Òȼº±Ë¾ç ¹× õ°øÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù. µå¹°°Ô ±Ë¾ç¼º Àå°áÀå¿°ÀÌ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¹Ç·Î ÀÌ·¯ÇÑ Áõ»óÀÌ ³ªÅ¸³¯ °æ¿ì¿¡´Â Åõ¿©¸¦ ÁßÁöÇÑ´Ù.
Ç÷¾×: µå¹°°Ô Àç»ýºÒ·®¼ººóÇ÷, Àû¾Æ±¸Áõ, Áø¼º ÀûÇ÷±¸Çü¼ººÎÀüÁõ(pure red cell aplasia) ¶§¶§·Î ºóÇ÷, ¹éÇ÷±¸°¨¼Ò, Ç÷¼ÒÆÇ°¨¼Ò, °ú¸³±¸°¨¼Ò, È£»ê±¸Áõ´Ù, È£Áß±¸°¨¼Ò µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¹Ç·Î ÀÌ·¯ÇÑ Áõ»óÀÌ ³ªÅ¸³¯ °æ¿ì¿¡´Â Åõ¿©¸¦ ÁßÁöÇÑ´Ù.
½ÅÀå: µå¹°°Ô ±Þ¼º½ÅºÎÀü, ½ÅÁõÈıº ¶ÇÇÑ ¶§¶§·Î BUN»ó½Â, ´Ü¹é´¢, Ç÷´¢ µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
°£Àå: ¶§¶§·Î GOT, GPT, AL-PÀÇ »ó½Â, Ȳ´ÞÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
È£Èí±â: µå¹°°Ô °£Áú¼ºÆó¿°ÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
±âŸ: ¶§¶§·Î ºÎÁ¾, üÁß°¨¼Ò, ¹Ì°¢ÀÌ»ó, ¹ß¿, ½É°èÇ×Áø, Å»·Â°¨, ºñÃâÇ÷, µÎÅë, À̸í, Çö±â, IgAÀúÇϰ¡ ³ªÅ¸³¯ ¼ö ÀÖ´Ù. Ä¡À°¿°, µå¹°°Ô ¿¬Çϰï¶õ, ¸»ÃÊ ½Å°æÀå¾Ö µîÀÇ ºÎÀÛ¿ëÀÌ º¸°íµÇ¾î ÀÖ´Ù.
|
| »óÈ£ÀÛ¿ë |
- ±ÝÁÖ»çÁ¦, ·¹¹Ù¹Ì¼Ö, È÷µå·ÎŬ·Î¸£Äý, ´ë·®ÀÇ ºÎ½ÅÇÇÁúÈ£¸£¸ó µî°ú º´¿ëÅõ¿©ÇÏÁö ¾Ê´Â´Ù.
- Ç׸»¶ó¸®¾ÆÁ¦, ¸é¿ª¾ïÁ¦Á¦, ÇǶóÁ¹·Ð À¯µµÃ¼ µîÀÇ Ç÷¾×Àå¾Ö°¡ ¹ß»ýÇÒ °¡´É¼ºÀÌ ÀÖ´Â ¾à¹° ¹× ų·¹ÀÌÆ® ÈÇÕ¹°(D-Æä´Ï½Ç¶ó¹Î)°ú º´¿ëÅõ¿©ÇÏÁö ¾Ê´Â °ÍÀÌ ¹Ù¶÷Á÷ÇÏ´Ù.
- µ¿¹°½ÃÇè¿¡¼ Äí¸¶¸°°è Ç×ÀÀÇ÷Á¦(¿Í¸£ÆÄ¸°)¿Í »óÈ£ÀÛ¿ëÀÌ º¸°íµÇ¾î ÀÖÀ¸¹Ç·Î º´¿ëÅõ¿©½Ã °¨·®ÇÏ´Â µî ½ÅÁßÈ÷ Åõ¿©ÇÑ´Ù.
- Æä´ÏÅäÀΰú º´¿ëÅõ¿©½Ã Æä´ÏÅäÀÎÀÇ Ç÷Áß³óµµ°¡ Áõ°¡Çß´Ù´Â º¸°í°¡ ÀÖ´Ù.
|
| Related FDA Approved Drug |
±âÁØ ¼ººÐ: AURANOFINRIDAURA (AURANOFIN)
|
|
|
 | Á¤º¸¿ä¾à |
|
|
|
µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸
|
|
 | ÄÚµå ¹× ºÐ·ùÁ¤º¸ |
|
|
| |
|
 | Á¦Ç°Á¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå »óÇÑ±Ý¾× |
[A12950761]
[º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸]
\0 ¿ø/1Á¤(2006.03.01)(Ãֽžడ)
\481 ¿ø/1Á¤(2001.09.01)(º¯°æÀü¾à°¡)
[»óº´ÄÚµåÁ¶È¸]
[Áúº´ÄÚµåÁý ´Ù¿î·Îµå]
|
| Á¦Ç°¼º»ó |
´ãȲ»ö ¿øÇüÀÇ Á¦ÇÇÁ¤
[Á¦ÇüÁ¤º¸ È®ÀÎ]
|
| Æ÷À塤À¯Åë´ÜÀ§ |
60TABS |
| º¸°ü¹æ¹ý |
¹ÐÆó¿ë±â, ½Ç¿Âº¸°ü |
µ¿ÀÏÁÖ¼ººÐÄÚµå °Ë»ö¼øÀ§ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| Brandname Á¤º¸ |
Auranofin
Brand Names/Synonyms
- Auroafen
- Ridaura
Brand Name MixturesNot Available
Chemical IUPAC Namegold(+1) cation; 3,4,5-triacetyloxy-6-(acetyloxymethyl)oxane-2-thiolate; triethylphosphanium
|
|
|
 | º¹¾àÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| LACTmed ¹Ù·Î°¡±â |
[¹Ù·Î°¡±â]
|
| ¾à¸®ÀÛ¿ë |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º¹¾àÁöµµ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| ÀӺο¡´ëÇÑÅõ¿© |
| * |
ÀüüÀӽŠ±â°£º°·Î ¿©·¯µî±ÞÀÌ Á¸ÀçÇÒ ¼ö ÀÖÀ¸¸ç °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ º¸¿©Áý´Ï´Ù. ´Ü, º¹ÇÕÁ¦ÀÇ °æ¿ì ¸ðµç º¹ÇÕÁ¦¼ººÐ¿¡ ´ëÇÑ ÀÓºÎÅõ¿©µî±ÞÀÌ Ç¥½ÃµÈ°ÍÀº Àý´ë ¾Æ´Ï¸ç Ç¥½ÃµÈ°ÍÁß¿¡ °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ ³ªÅ¸³³´Ï´Ù.
|
|
|   |
 FDA : Cµî±Þ
|
|
| * |
»ó±â ÀÓºÎÅõ¿©¿¡ ´ëÇÑ Á¤º¸´Â Àü»êó¸® µÇ¸é¼ ÀÔ·Â ¿À·ù °¡´É¼ºÀÌ Á¸ÀçÇÕ´Ï´Ù. ¿À·ù °¡´É¼ºÀ» ÃÖ¼ÒÈÇϱâ À§ÇÏ¿© ¸¹Àº ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖÀ¸³ª, ±× Á¤È®¼º¿¡ ´ëÇÏ¿© È®½ÅÀ» µå¸± ¼ö ¾ø½À´Ï´Ù. ÀÌ¿¡ ´ëÇØ ȸ»ç´Â Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù.
|
| * |
¹Ýµå½Ã °ø½Å·Â ÀÖ´Â ¹®ÇåÀ» ´Ù½Ã Çѹø Âü°í ÇϽñ⠹ٶó¸ç ÀÇ»ç ¶Ç´Â ¾à»çÀÇ ÆÇ´Ü¿¡ µû¶ó Åõ¿©¿©ºÎ°¡ °áÁ¤µÇ¾î¾ß ÇÕ´Ï´Ù.
|
|
|
½ÅÀå¾Ö, °£Àå¾Ö½Ã ¿ë·®Á¶Àý |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| Pharmacokinetics |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸ |
[º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸]
|
| º¹¾à¶óº§ |
| À̹ÌÁö |
º¹¾à¼³¸í |
 |
º¯ºñ°¡ »ý±æ¼ö ÀÖ½À´Ï´Ù. |
|
|
| * |
º¹¾àÀ̹ÌÁö´Â ¸ðµç º¹¾àÁöµµ »çÇ×À» Ç¥½ÃÇѰÍÀº ¾Æ´Ï¸ç, Ãß°¡ÀûÀ¸·Î ¾÷µ¥ÀÌÆ®µÇ°Å³ª ¼öÁ¤µÉ ¼ö ÀÖ½À´Ï´Ù. |
| * |
º¹¾àÀ̹ÌÁöÀÇ Ç¥½Ã¿©ºÎ´Â ½ÇÁ¦ ¾à¹°º¹¿ë½Ã Á߿䵵¿¡ µû¸¥°ÍÀº ¾Æ´Ï¸ç ´Ü¼øÈ÷ Çã°¡Á¤º¸»ó Ű¿öµå¸¦ ±âÁØÀ¸·Î µî·ÏµÇ¾ú½À´Ï´Ù. |
| * |
±ÍÇϰ¡ º¹¾àÀ̹ÌÁö Á¤º¸¸¦ ½Å·ÚÇÔÀº ÀüÀûÀ¸·Î ±ÍÇÏÀÇ Ã¥ÀÓÀÔ´Ï´Ù. µå·°ÀÎÆ÷´Â ÀÌ¿¡ ´ëÇÑ ¾î¶°ÇÑ º¸Áõµµ ÇÏÁö ¾Ê½À´Ï´Ù. |
|
|
| º¸°ü»ó ÁÖÀÇ |
|
| Á¶Á¦½Ã ÁÖÀÇ |
|
|
|
 | ½É»çÁ¤º¸ |
|
|
|
|
 | ÇмúÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| DUR (ÀǾàǰ»ç¿ëÆò°¡) |
º´¿ë±Ý±â :
°í½ÃµÈ º´¿ë±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[»óÈ£ÀÛ¿ë/º´¿ë±Ý±â°Ë»ö]
¿¬·É´ë±Ý±â :
°í½ÃµÈ ¿¬·É±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[¿¬·É´ë±Ý±â»ó¼¼°Ë»ö]
|
| Mechanism of Action |
Auranofin¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Exactly how auranofin works is not well understood. In patients with inflammatory arthritis, such as adult and juvenile rheumatoid arthritis, gold salts can decrease the inflammation of the joint lining. This effect can prevent destruction of bone and cartilage.
|
| Pharmacology |
Auranofin¿¡ ´ëÇÑ Pharmacology Á¤º¸ Auranofin is a gold salt used in treating inflammatory arthritis. Gold salts are called second-line drugs because they are often considered when the arthritis progresses in spite of antiinflammatory drugs (NSAIDs and corticosteroids).
|
| Protein Binding |
Auranofin¿¡ ´ëÇÑ ´Ü¹é°áÇÕ Á¤º¸ Not Available
|
| Half-life |
Auranofin¿¡ ´ëÇÑ ¹Ý°¨±â Á¤º¸ Not Available
|
| Absorption |
Auranofin¿¡ ´ëÇÑ Absorption Á¤º¸ Not Available
|
| Pharmacokinetics |
AuranofinÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
- Èí¼öÀ² : 25% (¹üÀ§ : 15-33%)
- ´Ü¹é°áÇÕ : 60%
- ¹Ý°¨±â : 26ÀÏ (¹üÀ§ : 21-31ÀÏ)
- Ç÷ÁßÃÖ°í³óµµ µµ´Þ½Ã°£ : 1-2 ½Ã°£
- ¼Ò½Ç : Åõ¿©·®ÀÇ 85-95%´Â ´ëº¯À» ÅëÇØ ¹è¼³µÇ¸ç, Èí¼öµÈ ¾çÀÇ 60%´Â ¼Òº¯À» ÅëÇØ ¹è¼³µÊ
|
| Biotransformation |
Auranofin¿¡ ´ëÇÑ Biotransformation Á¤º¸ Not Available
|
| Toxicity |
Auranofin¿¡ ´ëÇÑ Toxicity Á¤º¸ Oral, rat: LD50 = > 2000 mg/kg. Symptoms of overdose may include diarrhoea, vomiting, abdominal cramps, and symptoms of hypersensitivity (such as skin rash, hives, itching, and difficulty breathing).
|
| Drug Interactions |
Auranofin¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Not Available
|
CYP450 Drug Interaction |
[CYP450 TableÁ÷Á¢Á¶È¸]
|
| Food Interaction |
Auranofin¿¡ ´ëÇÑ Food Interaction Á¤º¸ Take with food to reduce irritation.
|
| Drug Target |
[Drug Target]
|
| Description |
Auranofin¿¡ ´ëÇÑ Description Á¤º¸ Auranofin is a organogold compound classified by the World Health Organization as an antirheumatic agent. Auranofin appears to induce heme oxygenase 1 (HO-1) mRNA. Heme oxygenase 1 is an inducible heme-degrading enzyme with anti-inflammatory properties.
|
| Dosage Form |
Auranofin¿¡ ´ëÇÑ Dosage_Form Á¤º¸ Capsule Oral
|
| Drug Category |
Auranofin¿¡ ´ëÇÑ Drug_Category Á¤º¸ Antirheumatic Agents, Gold
|
| Smiles String Canonical |
Auranofin¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ [Au+].CC[PH+](CC)CC.CC(=O)OCC1OC([S-])C(OC(C)=O)C(OC(C)=O)C1OC(C)=O
|
| Smiles String Isomeric |
Auranofin¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ [Au+].CC[PH+](CC)CC.CC(=O)OC[C@H]1O[C@@H]([S-])[C@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O
|
| InChI Identifier |
Auranofin¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C14H20O9S.C6H15P.Au/c1-6(15)19-5-10-11(20-7(2)16)12(21-8(3)17)13(14(24)23-10)22-9(4)18;1-4-7(5-2)6-3;/h10-14,24H,5H2,1-4H3;4-6H2,1-3H3;/q;;+1/fC14H19O9S.C6H16P.Au/h24h;7H;/q-1;+1;m
|
| Chemical IUPAC Name |
Auranofin¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ gold(+1) cation; 3,4,5-triacetyloxy-6-(acetyloxymethyl)oxane-2-thiolate; triethylphosphanium
|
| Drug-Induced Toxicity Related Proteins |
AURANOFIN ÀÇ Drug-Induced Toxicity Related ProteinÁ¤º¸ Replated Protein:Metallothionein Drug:auranofin Toxicity:persistent loose stools. [¹Ù·Î°¡±â]
|
|
|
 | »ç¿ëÀÚÄÁÅÙÃ÷ |
|
|
|
|
|
-
ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2015-02-05
-
º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
|
|
¾Ë¸² |
»ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù. |
|
°æ°í |
µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù.
Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â
Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡±¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù.
ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
|
|
¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é
¿©±â·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ
[ÀǾàǰº´¿ë/¿¬·É´ë±Ý±â °í½Ã±Ù°Å·Î ¹Ù·Î°¡±â] Á¦¸ñ ¾øÀ½
2008³â 8¿ù 1ÀÏ ¾à°¡ÈÀÏ»ó 8¿ù´Þ ½Å±ÔµîÀç ¹× »èÁ¦µÇ´Â ǰ¸ñ Æ÷ÇÔÇÑ º´¿ë¿¬·É ±Ý±â ǰ¸ñ¸®½ºÆ® ±âÁØ
1. ÇöÀç °Ë»öÇÑ Á¦Ç°¿¡ ´ëÇÑ º´¿ë±Ý±â Á¦Ç° Á¸Àç¿©ºÎ ¹× °Ë»ö
ÇöÀç ÀÌÁ¦Ç°¿¡ ´ëÇÑ º´¿ë±Ý±â¿¡ ÇØ´çÇϴ û±¸Äڵ庰 Á¦Ç°³»¿ª °øÁö³»¿ëÀÌ ¾ø½À´Ï´Ù
2. ¿¬·É´ë±Ý±â Á¸Àç¿©ºÎ
ÇöÀç ÀÌÁ¦Ç°¿¡ ´ëÇÑ ¿¬·É±Ý±â¿¡ ÇØ´çÇϴ û±¸Äڵ庰 °øÁö³»¿ëÀÌ ¾ø½À´Ï´Ù
|